loading page

A systematic review and meta-analysis of new-onset atrial fibrillation in the context of COVID-19
  • +9
  • Sawai Singh Rathore,
  • Akanksha Atulkar,
  • Kavya Remala,
  • Vanessa Vidaurre Corrales,
  • Ameer Mustafa Farrukh,
  • Ravinderjeet Kaur Puar,
  • Sem Josue Nsanh Yao,
  • Vijaya Durga Pradeep Ganipineni,
  • Nirmal Patel,
  • Naganath Thota,
  • Ashish Kumar,
  • Abhishek Deshmukh
Sawai Singh Rathore
Dr Sampurnanand Medical College
Author Profile
Akanksha Atulkar
Global Remote Research Scholars Program
Author Profile
Kavya Remala
Konaseema Institute of Medical Sciences and Research Foundation Hospital
Author Profile
Vanessa Vidaurre Corrales
Universidad del Valle
Author Profile
Ameer Mustafa Farrukh
National University of Ireland Galway Academic Department of Paediatrics
Author Profile
Ravinderjeet Kaur Puar
Vardhman Mahavir Medical College and Safdarjung Hospital
Author Profile
Sem Josue Nsanh Yao
Cincinnati Children's Hospital Medical Center Winslow
Author Profile
Vijaya Durga Pradeep Ganipineni
Andhra Medical College
Author Profile
Nirmal Patel
St George's University School of Medicine
Author Profile
Naganath Thota
Baptist Memorial Rehabilitation Hospital
Author Profile
Ashish Kumar
Cleveland Clinic Akron General Department of Internal Medicine
Author Profile
Abhishek Deshmukh
Mayo Clinic Department of Cardiovascular Medicine

Corresponding Author:[email protected]

Author Profile


Background: New-onset atrial fibrillation (NOAF) in COVID-19 raises significant clinical and public health issues. This systematic review and meta-analysis aims to compile and analyze the current literature on NOAF in COVID-19 and give a more comprehensive understanding of the prevalence and outcomes of NOAF in COVID-19. Methods: A comprehensive literature search was carried out using several databases. The random effect model using inverse variance method and DerSimonian and Laird estimator of Tua2 was used to calculate the pooled prevalence and associated 95% confidence interval (CI). Results for outcome analysis were presented as odds ratios (ORs) with 95% CI and pooled using the Mantel-Haenszel random-effects model. Results: The pooled prevalence of NOAF in COVID-19 was 7.8% (95% CI, 6.54% to 9.32%), pooled estimate from 30 articles (81,929 COVID-19 patients). Furthermore, our analysis reported that COVID-19 patients with NOAF had a higher risk of developing severe disease compared with COVID–19 patients without a history of atrial fibrillation (OR= 4.78, 95% CI 3.75 to 6.09) and COVID-19 patients with a history of pre-existing atrial fibrillation (OR= 2.75, 95% CI 2.10 to 3.59) . Similarly, our analysis also indicated that COVID–19 patients with NOAF had a higher risk of all-cause mortality compared with, COVID–19 patients without a history of atrial fibrillation (OOR= 3.83, 95% CI 2.99 to 4.92) and COVID-19 patients with a history of pre-existing atrial fibrillation (OR= 2.32, 95% CI 1.35 to 3.96). The meta-analysis did not reveal any significant publication bias. Conclusion: The results of the current meta-analysis a high prevalence rate of NOAF among COVID-19 patients. Further the study reported higher disease severity with NOAF compared with COVID-19 patients without a history of atrial fibrillation and with a history of atrial fibrillation.
18 Oct 2023Submitted to Journal of Cardiovascular Electrophysiology
18 Oct 2023Assigned to Editor
18 Oct 2023Submission Checks Completed
18 Oct 2023Review(s) Completed, Editorial Evaluation Pending
21 Oct 2023Reviewer(s) Assigned
10 Nov 2023Editorial Decision: Revise Minor